Evidence map›Paper›PMID 39907983›Full record

ArticleDrug safety2025

Delphi Method Consensus on Statistical Analysis and Reporting Recommendations for Single-Arm Pregnancy Medication Safety Studies Investigating Pregnancy, Birth and Neonatal Health Outcomes: A Contribution from IMI-ConcePTION.

Jonathan L Richardson, Alan Moore, Michael Stellfeld, Yvonne Geissbühler, Ursula Winterfeld, Guillaume Favre, Christina Chambers, Evelin Beck, Marlies Onken, Katarina Dathe and 10 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jonathan L RichardsonUK Teratology Information Service, The Regional Drug and Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, 16/17 Framlington Place, Newcastle upon Tyne, Tyne and Wear, NE2 4AB, UK. jonathan.richardson3@nhs.net.ORCID http://orcid.org/0000-0003-3494-9559
Alan MooreNovartis Pharma AG, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6049-2540
Michael StellfeldNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0009-0004-3003-1382
Yvonne GeissbühlerNovartis Pharma AG, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0001-8528-6818
Ursula WinterfeldSwiss Teratology Information Service and Clinical Pharmacology Service, University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9926-7164
Guillaume FavreSwiss Teratology Information Service and Clinical Pharmacology Service, University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-6181-3126
Christina ChambersDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4675-7722
Evelin BeckInstitute of Clinical Pharmacology and Toxicology, Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-1008-8563
Marlies OnkenInstitute of Clinical Pharmacology and Toxicology, Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-4385-612X
Katarina DatheInstitute of Clinical Pharmacology and Toxicology, Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-8674-5817
Michael CeulemansResearch Group Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4130-5869
Orna Diav-CitrinThe Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-7165-113X
Svetlana ShechtmanThe Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel.ORCID http://orcid.org/0000-0003-0234-7019
Alison M OliverUK Teratology Information Service, The Regional Drug and Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, 16/17 Framlington Place, Newcastle upon Tyne, Tyne and Wear, NE2 4AB, UK.ORCID http://orcid.org/0000-0002-4564-9984
Kenneth K HodsonUK Teratology Information Service, The Regional Drug and Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, 16/17 Framlington Place, Newcastle upon Tyne, Tyne and Wear, NE2 4AB, UK.ORCID http://orcid.org/0000-0003-3091-6952
Dee-Dee ShillerAbbVie Clinical Pharmacology Research Unit, AbbVie Inc., Grayslake, IL, USA.ORCID http://orcid.org/0009-0005-5393-6552
Amalia AlexeNovartis Pharma AG, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3016-8579
Eugène P van PuijenbroekPharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.ORCID http://orcid.org/0000-0002-2236-1398
David J LewisNovartis Pharma AG, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0001-9576-3489
Laura M YatesInstitute of Genetic Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-7963-625X

Funding

Innovative Medicines Initative (EU) call 13Innovative Medicines Initative (EU) grant agreement number 821520Innovative Medicines Initative (EU) topic 9
6 · The paper itself

Abstract

BACKGROUND AND

objectiveStandardised procedures for performing and reporting safety monitoring studies investigating medications use in pregnancy may help improve data quality and the speed of data generation. The objective of this study was to provide recommendations on the statistical analysis and reporting of single-arm pregnancy medication safety studies using primary source datasets.

methodsA Delphi consensus-setting protocol was used to acquire agreement on recommendations from experts with extensive knowledge and experience in conducting studies investigating medication safety in pregnancy. A series of recommendations, along with their scientific justifications and examples of how to calculate and describe exposure and outcome incidences, were critiqued and improved through a series of online Delphi review rounds. Agreement to inclusion scoring was assessed using a five-point Likert scale. Recommendations with a median Likert-scale score of at least 4, where ≥ 80% of the expert panel scored the recommendation at level 4 or higher, was used as the threshold for inclusion.

resultsThe Delphi consensus methodology produced a set of 30 recommendations spread over five themes. These included descriptions of (1) study sample, (2) medication exposure, (3) maternal outcomes, (4) pregnancy and birth outcomes, and (5) fetal and neonatal outcomes. Of the 30 recommendations, 19 were strongly advised while 11 were included for consideration where their implementation may be beneficial for supplementing data communication.

conclusionUse of the finalised set of recommendations should be encouraged to help standardise published evidence around medication use in pregnancy.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsData Interpretation, StatisticalDelphi TechniqueFemaleHumansInfant, NewbornPregnancyPregnancy ComplicationsPregnancy Outcome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.